UBS AM
CLVS

UBS AM’s Clovis Oncology, Inc. CLVS Stock Holding History

UBS AM’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-98,191
Closed -$198K – 2815
2022
Q1 		$198K Hold
98,191
– – ﹤0.01% 2684
2021
Q4 		$266K Hold
98,191
– – ﹤0.01% 2707
2021
Q3 		$438K Sell
98,191
-29,175
-23% -$141K ﹤0.01% 2548
2021
Q2 		$739K Buy
127,366
+50,162
+65% +$294K ﹤0.01% 2364
2021
Q1 		$542K Sell
77,204
-2,915
-4% -$19.5K ﹤0.01% 2358
2020
Q4 		$385K Buy
80,119
+2,107
+3% +$10.7K ﹤0.01% 2369
2020
Q3 		$455K Sell
78,012
-1,743
-2% -$10.4K ﹤0.01% 2183
2020
Q2 		$538K Buy
+79,755
New +$604K ﹤0.01% 2096
2019
Q4 		– Sell
-56,185
Closed -$221K – 2910
2019
Q3 		$221K Buy
56,185
+17,138
+44% +$139K ﹤0.01% 2551
2019
Q2 		$581K Buy
39,047
+4,571
+13% +$82.6K ﹤0.01% 2147
2019
Q1 		$856K Buy
34,476
+15,587
+83% +$391K ﹤0.01% 1884
2018
Q4 		$339K Sell
18,889
-88,452
-82% -$1.81M ﹤0.01% 2154
2018
Q3 		$3.15M Buy
107,341
+2,238
+2% +$86.6K ﹤0.01% 1312
2018
Q2 		$4.78M Sell
105,103
-315,002
-75% -$15.3M ﹤0.01% 1163
2018
Q1 		$22.2M Sell
420,105
-131,977
-24% -$7.7M 0.02% 742
2017
Q4 		$37.5M Buy
552,082
+178,337
+48% +$12.5M 0.03% 543
2017
Q3 		$30.8M Buy
373,745
+89,264
+31% +$7.08M 0.03% 597
2017
Q2 		$26.6M Buy
284,481
+12,389
+5% +$758K 0.03% 635
2017
Q1 		$17.3M Buy
272,092
+17,450
+7% +$1.06M 0.02% 760
2016
Q4 		$11.3M Sell
254,642
-7,576
-3% -$267K 0.01% 839
2016
Q3 		$9.45M Buy
262,218
+249,929
+2,034% +$5.36M 0.01% 895
2016
Q2 		$169K Hold
12,289
– – ﹤0.01% 2493
2016
Q1 		$236K Sell
12,289
-1,200
-9% -$25.4K ﹤0.01% 2347
2015
Q4 		$472K Sell
13,489
-6,828
-34% -$440K ﹤0.01% 2088
2015
Q3 		$1.87M Buy
20,317
+8,717
+75% +$754K ﹤0.01% 1465
2015
Q2 		$1.02M Buy
11,600
+3,000
+35% +$257K ﹤0.01% 1672
2015
Q1 		$638K Buy
8,600
+400
+5% +$28.2K ﹤0.01% 1842
2014
Q4 		$459K Buy
8,200
+700
+9% +$36.8K ﹤0.01% 1989
2014
Q3 		$340K Hold
7,500
– – ﹤0.01% 2075
2014
Q2 		$311K Hold
7,500
– – ﹤0.01% 2159
2014
Q1 		$520K Buy
7,500
+400
+6% +$29.4K ﹤0.01% 1870
2013
Q4 		$428K Buy
7,100
+2,400
+51% +$131K ﹤0.01% 1895
2013
Q3 		$286K Buy
+4,700
New +$333K ﹤0.01% 2112

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

UBS AM's CLVS Position: Q2 2022 in Review

UBS AM sold out of Clovis Oncology, Inc. (CLVS) in Q2 2022, closing a stake of 98,191 shares — an estimated $198K sold.

UBS AM first reported a position in CLVS in Q3 2013 and held it in 33 quarters. The position peaked at $37.5M in Q4 2017. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

  • UBS AM reported no remaining Clovis Oncology, Inc. position as of Q2 2022 after selling out during the quarter.
  • UBS AM sold 98,191 Clovis Oncology, Inc. shares in Q2 2022, an estimated $198K.
  • UBS AM first reported a position in Clovis Oncology, Inc. in Q3 2013 and held it in 33 quarters.
  • UBS AM's Clovis Oncology, Inc. position peaked at $37.5M in Q4 2017.
  • 115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on UBS AM's 13F filing for Q2 2022, filed 12 Aug 2022.